Distributional impact of rotavirus vaccination in 25 GAVI countries: Estimating disparities in benefits and cost-effectiveness

Vaccine

Volumn 30, Issue SUPPL. 1, 2012, Pages

  Rheingans, Richard ^a   Atherly, Deborah ^b   Anderson, John ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b PATH   (United States)

Author keywords

Cost effectiveness; Disparities; Equity; Rotavirus; Vaccination

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; GEOGRAPHIC DISTRIBUTION; HEALTH CARE DISPARITY; HEALTH SURVEY; HUMAN; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ROTAVIRUS INFECTION; VACCINATION;

COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DIARRHEA; HUMANS; IMMUNIZATION PROGRAMS; INDIA; INFANT; INFANT, NEWBORN; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 84860002663     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.018     Document Type: Article

References (33)

1. Atherly D., Dreibelbis R., Parashar U.D., Levin C., Wecker J., Rheingans R.D. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. The Journal of Infectious Diseases 2009, 200(S1):S28-S38.
2. Podewils L.J., Antil L., Hummelman E., Bresee J., Parashar U.D., Rheingans R. Projected cost-effectiveness of rotavirus vaccination for children in Asia. The Journal of Infectious Diseases 2005, 192(S1):S133-S145.
3. Rheingans R.D., Antil L., Dreibelbis R., Podewils L.J., Bresee J.S., Parashar U.D. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. The Journal of Infectious Diseases 2009, 200(S1):S16-S27.
4. Rheingans R.D., Constenla D., Antil L., Innis B.L., Breuer T. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Revista Panamericana de Salud Publica 2007, 21:205-216.
5. Atherly D., Lewis K., Tate J.E., Parashar U.D., Rheingans R.D. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030. Vaccine 2012, 10.1016/j.vaccine.2011.12.096.
6. Tate J.E., Rheingans R.D., O'Reilly C.E., Obonyo B., Burton D.C., Tornheim J.A., et al. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in Kenya. Journal of Infectious Diseases 2009, 200(November (Suppl. 1)):S76-S84.
7. Bishai D., Koenig M., Khan M.A. Measles vaccination improves the equity of health outcomes: evidence from Bangladesh. Health Economics 2003, 12(5):415-419.
8. Michaelidis C.I., Zimmerman R.K., Nowalk M.P., Smith K.J. Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups. Vaccine 2011, 29(19):3525-3530.
9. Pallecaros A., Vonau B. Human papilloma virus vaccine - more than a vaccine. Current Opinion in Obstetrics and Gynecology 2007, 19(December (6)):541-546.
10. Tsu V.D. Overcoming barriers and ensuring access to HPV vaccines in low-income countries. American Journal of Law & Medicine 2009, 35(2-3):401-413.
11. Lindholm L., Rosen M., Emmelin M. How many lives is equity worth? A proposal for equity adjusted years of life saved. Journal of Epidemiology & Community Health 1998, 52(December (12)):808-811.
12. Wailoo A., Tsuchiya A., McCabe C. Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected. Pharmacoeconomics 2009, 27(12):983-989.
13. Stolk E.A., van Donselaar G., Brouwer W.B., Busschbach J.J. Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall. Pharmacoeconomics 2004, 22(17):1097-1107.
14. Epstein D.M., Chalabi Z., Claxton K., Sculpher M. Efficiency, equity, and budgetary policies: informing decisions using mathematical programming. Medical Decision Making 2007, 27(March-April (2)):128-137.
15. Walensky R.P., Wood R., Ciaranello A.L., Paltiel A.D., Lorenzana S.B., Anglaret X., et al. Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Medicine 2010, 7(12):1-12.
16. Jehu-Appiah C., Baltussen R., Acquah C., Aikins M., d' Almeida S.A., Bosu W.K., et al. Balancing equity and efficiency in health priorities in Ghana: the use of multicriteria decision analysis. Value in Health 2008, 11(December (7)):1081-1087.
17. Coyle D., Buxton M.J., O'Brien B.J. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. Health Economics 2003, 12(5):421-427.
18. Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics 2008, 26(9):799-806.
19. Tate J.E., Burton A.H., Boschi-Pinto C., Steele A.D., Duque J., Parashar U. Global mortality associated with rotavirus disease among children in 2008: findings based on a systematic review and meta-analysis. Lancet Infectious Diseases 2011, 12(2):136-141.
20. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A., Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerging Infectious Diseases 2003, 9(May (50)):565-572.
21. Madhi S.A., Cunliffe N.A., Steele D., Witte De, Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine 2010, 362(4):289-298.
22. De Vos B., Vesikari T., Linhares A.C., Salinas B., Pérez-Schael I., Ruiz-Palacios G.M., et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. The Pediatric Infectious Disease Journal 2004, 23(10):S179-S182.
23. Ruiz-Palacios G., Peórez-Schael I., Velaózquez F., Abate H., Breuer T., Clemens S., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine 2006, 354(1):11-22.
24. Clark A., Sanderson C. Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. The Lancet 2009, 373(May (9674)):1543-1549.
25. Patel M.M., Clark A.D., Glass R.I., Greenberg H., Tate J., Santosham M., et al. Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception. Vaccine 2009, 27(May (22)):2916-2922.
26. Demographic and health surveys: STATcompiler. Available at: [accessed 21.03.11]. http://www.statcompiler.com/.
27. Caulfield L.E., de Onis M., Blossner M., Black R.E. Undernutrition as an underlying cause of child deaths associated with diarrhea, pneumonia, malaria, and measles. American Journal of Clinical Nutrition 2004, 80(July (1)):193-198.
28. Esposito D.H., Tate J.E., Kang G., Parashar U.D. Projected impact and cost-effectiveness of a rotavirus vaccination program in India, 2008. Clinical Infectious Diseases 2011, 52(January (2)):171-177.
29. O'Donnell O., van Doorslaer E., Wagstaff A., Lindelow M. Analyzing Health Equity Using Household Survey Data: a guide to techniques and their implementation 2008, The World Bank, Washington, DC.
30. Noor A.M., Mutheu J.J., Tatem A.J., Hay S.I., Snow R.W. Insecticide-treated net coverage in Africa: mapping progress in 2000-07. Lancet 2009, 373(January (9657)):58-67.
31. Pullan R.L., Gething P.W., Smith J.L., Mwandawiro C.S., Sturrock H.J., Gitonga C.W., et al. Spatial modelling of soil-transmitted helminth infections in Kenya: a disease control planning tool. PLoS Neglected Tropical Diseases 2011, 5(2):e958.
32. Barham T., Maluccio J.A. Eradicating diseases: the effect of conditional cash transfers on vaccination coverage in rural Nicaragua. Journal of Health Economics 2009, 28(May (3)):611-621.
33. Lagarde M., Haines A., Palmer N. Conditional cash transfers for improving uptake of health interventions in low- and middle-income countries: a systematic review. JAMA 2007, 298(October (16)):1900-1910.